» Articles » PMID: 28403943

Plasma Metabolomics in Adults with Cystic Fibrosis During a Pulmonary Exacerbation: A Pilot Randomized Study of High-dose Vitamin D Administration

Abstract

Background: Cystic fibrosis (CF) is a chronic catabolic disease often requiring hospitalization for acute episodes of worsening pulmonary exacerbations. Limited data suggest that vitamin D may have beneficial clinical effects, but the impact of vitamin D on systemic metabolism in this setting is unknown.

Objective: We used high-resolution metabolomics (HRM) to assess the impact of baseline vitamin D status and high-dose vitamin D administration on systemic metabolism in adults with CF with an acute pulmonary exacerbation.

Design: Twenty-five hospitalized adults with CF were enrolled in a randomized trial of high-dose vitamin D (250,000IU vitamin D bolus) versus placebo. Age-matched healthy subjects served as a reference group for baseline comparisons. Plasma was analyzed with liquid chromatography/ultra-high resolution mass spectrometry. Using recent HRM bioinformatics and metabolic pathway enrichment methods, we examined associations with baseline vitamin D status (sufficient vs. deficient per serum 25-hydroxyvitamin D concentrations) and the 7-day response to vitamin D supplementation.

Results: Several amino acids and lipid metabolites differed between CF and healthy control subjects, indicative of an overall catabolic state. In CF subjects, 343 metabolites differed (P<0.05) by baseline vitamin D status and were enriched within 7 metabolic pathways including fatty acid, amino acid, and carbohydrate metabolism. A total of 316 metabolites, which showed enrichment for 15 metabolic pathways-predominantly representing amino acid pathways-differed between the vitamin D- and placebo-treated CF subjects over time (P<0.05). In the placebo group, several tricarboxylic acid cycle intermediates increased while several amino acid-related metabolites decreased; in contrast, little change in these metabolites occurred with vitamin D treatment.

Conclusions: Numerous metabolic pathways detected by HRM varied in association with vitamin D status and high-dose vitamin D supplementation in adults with CF experiencing a pulmonary exacerbation. Overall, these pilot data suggest an anti-catabolic effect of high-dose vitamin D in this clinical setting.

Citing Articles

Impact of high-dose cholecalciferol (vitamin D3) and inulin prebiotic on intestinal and airway microbiota in adults with cystic fibrosis: A 2 × 2 randomized, placebo-controlled, double-blind pilot study.

Suppakitjanusant P, Wang Y, Sivapiromrat A, Hu C, Binongo J, Hunt W J Clin Transl Endocrinol. 2024; 37:100362.

PMID: 39188269 PMC: 11345930. DOI: 10.1016/j.jcte.2024.100362.


High-resolution plasma metabolomics and thiamine status in critically Ill adult patients.

Gundogan K, Nellis M, Ozer N, Ergul S, Sahin G, Temel S Metabolomics. 2024; 20(4):83.

PMID: 39066851 PMC: 11283406. DOI: 10.1007/s11306-024-02144-9.


Standard Doses of Cholecalciferol Reduce Glucose and Increase Glutamine in Obesity-Related Hypertension: Results of a Randomized Trial.

Santos C, Carvalho R, Fonseca A, Branco M, Alves M, Jarak I Int J Mol Sci. 2024; 25(6).

PMID: 38542390 PMC: 10969945. DOI: 10.3390/ijms25063416.


Vitamin D and prebiotics for intestinal health in cystic fibrosis: Rationale and design for a randomized, placebo-controlled, double-blind, 2 x 2 trial of administration of prebiotics and cholecalciferol (vitamin D) (Pre-D trial) in adults with....

Sivapiromrat A, Suppakitjanusant P, Wang Y, Hu C, Binongo J, Hunt W Contemp Clin Trials Commun. 2024; 38:101278.

PMID: 38435430 PMC: 10904905. DOI: 10.1016/j.conctc.2024.101278.


Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis: Rationale and design for a randomized, placebo-controlled, double-blind, 2 × 2 trial of administration of prebiotics and cholecalciferol (vitamin D) (Pre-D Trial) in adults with....

Sivapiromrat A, Suppakitjanusant P, Wang Y, Binongo J, Hunt W, Gewirtz A medRxiv. 2024; .

PMID: 38343811 PMC: 10854319. DOI: 10.1101/2024.01.04.24300860.


References
1.
Tangpricha V, Kelly A, Stephenson A, Maguiness K, Enders J, Robinson K . An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab. 2012; 97(4):1082-93. DOI: 10.1210/jc.2011-3050. View

2.
Carlberg C . Genome-wide (over)view on the actions of vitamin D. Front Physiol. 2014; 5:167. PMC: 4010781. DOI: 10.3389/fphys.2014.00167. View

3.
Spoonhower K, Davis P . Epidemiology of Cystic Fibrosis. Clin Chest Med. 2016; 37(1):1-8. DOI: 10.1016/j.ccm.2015.10.002. View

4.
Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G . Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. Physiol Rev. 2015; 96(1):365-408. PMC: 4839493. DOI: 10.1152/physrev.00014.2015. View

5.
Go Y, Liang Y, Uppal K, Soltow Q, Promislow D, Wachtman L . Metabolic Characterization of the Common Marmoset (Callithrix jacchus). PLoS One. 2015; 10(11):e0142916. PMC: 4651467. DOI: 10.1371/journal.pone.0142916. View